RVMD Stock Forecast 2025-2026
Distance to RVMD Price Targets
RVMD Price Momentum
10 Quality Stocks Worth Considering Now
Researching Revolution Medicines (RVMD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RVMD and similar high-potential opportunities.
Latest RVMD Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, RVMD has a bullish consensus with a median price target of $71.50 (ranging from $59.00 to $87.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $36.76, the median forecast implies a 94.5% upside. This outlook is supported by 13 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Schmidt at Guggenheim, projecting a 136.7% upside. Conversely, the most conservative target is provided by Ami Fadia at Needham, suggesting a 60.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RVMD Analyst Ratings
RVMD Price Target Range
Latest RVMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RVMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2025 | Needham | Ami Fadia | Buy | Reiterates | $59.00 |
| Apr 1, 2025 | Stifel | Benjamin Burnett | Buy | Maintains | $64.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $73.00 |
| Feb 27, 2025 | Stifel | Benjamin Burnett | Buy | Maintains | $78.00 |
| Feb 27, 2025 | Needham | Ami Fadia | Buy | Maintains | $59.00 |
| Jan 8, 2025 | UBS | Eliana Merle | Buy | Maintains | $71.00 |
| Dec 6, 2024 | Needham | Ami Fadia | Buy | Maintains | $62.00 |
| Dec 6, 2024 | Wedbush | Robert Driscoll | Outperform | Maintains | $67.00 |
| Dec 4, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $72.00 |
| Dec 3, 2024 | Guggenheim | Michael Schmidt | Buy | Maintains | $87.00 |
| Dec 3, 2024 | Needham | Ami Fadia | Buy | Reiterates | $68.00 |
| Dec 3, 2024 | JP Morgan | Eric Joseph | Overweight | Maintains | $71.00 |
| Nov 7, 2024 | JP Morgan | Eric Joseph | Overweight | Maintains | $63.00 |
| Nov 7, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $70.00 |
| Nov 7, 2024 | Wedbush | Outperform | Maintains | $0.00 | |
| Nov 7, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $64.00 |
| Nov 7, 2024 | Needham | Ami Fadia | Buy | Maintains | $68.00 |
| Oct 28, 2024 | Needham | Ami Fadia | Buy | Reiterates | $61.00 |
| Oct 28, 2024 | Guggenheim | Michael Schmitz | Buy | Maintains | $82.00 |
| Oct 28, 2024 | Oppenheimer | Jay Olson | Outperform | Maintains | $60.00 |
Revolution Medicines Inc. (RVMD) Competitors
The following stocks are similar to Revolution Medicines based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Revolution Medicines Inc. (RVMD) Financial Data
Revolution Medicines Inc. has a market capitalization of $6.83B with a P/E ratio of -10.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -29.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Revolution Medicines Inc. (RVMD) Business Model
About Revolution Medicines Inc.
Develops targeted therapies for cancer treatment.
The company generates revenue by developing innovative cancer drugs that target specific oncogenic pathways. It leverages partnerships with academic institutions and biopharmaceutical companies to enhance its research and development efforts, focusing on synthetic lethal technologies and non-covalent inhibitors.
Revolution Medicines Inc. is deeply committed to advancing precision medicine in oncology, aiming to improve patient outcomes through its innovative drug candidates. The company's strong emphasis on R&D positions it as a significant player in the evolving landscape of cancer treatment.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
534
CEO
Dr. Mark A. Goldsmith Ph.D.
Country
United States
IPO Year
2020
Website
www.revmed.comRevolution Medicines Inc. (RVMD) Latest News & Analysis
Revolution Medicines, Inc. (Nasdaq: RVMD) will present 11 studies at the AACR Annual Meeting in Chicago from April 25-30, 2025, focusing on therapies for RAS-addicted cancers.
Revolution Medicines' presentations at AACR could highlight advancements in their therapies, potentially influencing stock performance and investor sentiment in the oncology sector.
Revolution Medicines, Inc. (Nasdaq: RVMD) will have CEO Mark A. Goldsmith participate in two investor conferences, focusing on targeted therapies for RAS-addicted cancers.
Mark A. Goldsmith's participation in investor conferences signals potential updates on Revolution Medicines' clinical progress, impacting investor sentiment and stock performance.
Revolution Medicines, Inc. will host its Q4 2024 Earnings Conference Call on February 26, 2025, at 4:30 PM ET, featuring key executives and analysts from various firms.
The upcoming earnings call for Revolution Medicines could reveal key financial performance and strategic updates, impacting investor sentiment and stock valuation.
Revolution Medicines aims to complete enrollment in the Phase 3 RASolute 302 trial for daraxonrasib in metastatic pancreatic cancer by year-end, with data expected in 2026. New trials for lung cancer are also being initiated.
The advancement of daraxonrasib trials signals potential breakthroughs in cancer treatment, impacting future revenue and stock performance. Upcoming data readouts could influence investor sentiment significantly.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced leadership changes on February 24, 2025, focusing on its late-stage clinical development of targeted therapies for RAS-addicted cancers.
Revolution Medicines’ announcement may indicate a significant development in their drug pipeline, potentially impacting stock performance and investor sentiment regarding RAS-targeted therapies.
Revolution Medicines, Inc. (Nasdaq: RVMD) will report Q4 and full-year 2024 financial results on February 26, 2025, after market close. A management webcast is scheduled for 4:30 p.m. ET.
Revolution Medicines' upcoming financial results and corporate update could influence stock performance, reflecting investor sentiment on the company's progress in oncology therapies.
Frequently Asked Questions About RVMD Stock
What is Revolution Medicines Inc.'s (RVMD) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, Revolution Medicines Inc. (RVMD) has a median price target of $71.50. The highest price target is $87.00 and the lowest is $59.00.
Is RVMD stock a good investment in 2025?
According to current analyst ratings, RVMD has 13 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $36.76. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RVMD stock?
Wall Street analysts predict RVMD stock could reach $71.50 in the next 12 months. This represents a 94.5% increase from the current price of $36.76. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Revolution Medicines Inc.'s business model?
The company generates revenue by developing innovative cancer drugs that target specific oncogenic pathways. It leverages partnerships with academic institutions and biopharmaceutical companies to enhance its research and development efforts, focusing on synthetic lethal technologies and non-covalent inhibitors.
What is the highest forecasted price for RVMD Revolution Medicines Inc.?
The highest price target for RVMD is $87.00 from Michael Schmidt at Guggenheim, which represents a 136.7% increase from the current price of $36.76.
What is the lowest forecasted price for RVMD Revolution Medicines Inc.?
The lowest price target for RVMD is $59.00 from Ami Fadia at Needham, which represents a 60.5% increase from the current price of $36.76.
What is the overall RVMD consensus from analysts for Revolution Medicines Inc.?
The overall analyst consensus for RVMD is bullish. Out of 18 Wall Street analysts, 13 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $71.50.
How accurate are RVMD stock price projections?
Stock price projections, including those for Revolution Medicines Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.